- $1.22bn
- $1.17bn
- $30.91m
Verastem Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635
Verastem Inc expected to post a loss of 95 cents a share - Earnings Preview
Brief: Verastem Oncology Receives FDA Orphan Drug Designation For Avutometinib And Defactinib
U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust
U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics
U.S. STOCKS ON THE MOVE-Estee Lauder, Enphase, GE Vernova
Verastem sinks on $55 mln stock-and-warrants offering
Brief: Verastem Inc Prices Its Underwritten Public Offering Of 13.3 Million Shares At $3.00 Per Share
U.S. RESEARCH ROUNDUP-Civitas Resources, GDS Holdings, Spirit Aerosystems
U.S. RESEARCH ROUNDUP- Ulta Beauty, Workday, Zscaler
U.S. STOCKS ON THE MOVE-Gold miners, Dell, Nutanix
U.S. STOCKS ON THE MOVE-XPO, Howmet Aerospace, Martin Midstream
U.S. STOCKS ON THE MOVE-Guardant Health, Lucid, Shift4 Payments
U.S. STOCKS ON THE MOVE-Iovance Biotherapeutics, The9, Guardant Health
Verastem surges on positive pancreatic cancer treatment trial
Brief: Verastem Oncology Announces Positive Initial Interim Safety And Efficacy Results From RAMP 205 Trial Evaluating Avutometinib Plus Defactinib In Combination With Gemcitabine And NAB-Paclitaxel In First-Line Metastatic Pancreatic Cancer
Verastem Inc reports results for the quarter ended in March - Earnings Summary
Verastem Inc expected to post a loss of $1.03 a share - Earnings Preview